AXON's Alzheimer’s vaccine completes Phase 1 trial
AXON, a biotech firm, said it created the vaccine to give hope to the millions of people afflicted with Alzheimer’s, their caregivers, their loved ones and their physicians.
The vaccine was engineered to stimulate the immune system into attacking tau proteins that are diseased. This could stop Alzheimer’s disease from progressing.
The completion of the safety trial marks AXON as the first company that has successfully finished its Phase 1 study for an active immunotherapy treatment designed to address diseased tau proteins, which are the proteins that cause Alzheimer’s patients to have neural degeneration.
"The first phase of clinical trials shows that we've managed to build a robust and safe vaccine for AD,” AXON Co-founder and Chief Science Officer Michal Novak said. “That was the task of the first phase, which was met 100 percent."
AXON said it will present the the Phase 1 study results at its symposium at the Alzheimer’s Association International Conference, which, will take place at Marriot Marquis Hotel in Washington, D.C., at 6 pm on July 22.
"We believe that our vaccine can be the first Alzheimer's disease modifying drug in the market,” AXON CEO Roman Sivak said.